Avalo Therapeutics (AVTX) Change in Accured Expenses (2014 - 2026)
Avalo Therapeutics posted quarterly Change in Accured Expenses of -$1.5 million for Q1 2026, up 12.06% year-on-year from -$1.3 million in Q1 2025, and down 127.94% on a QoQ basis from $5.4 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Change in Accured Expenses data on file, last reported at -$1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 12.06% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (up 692.49% YoY), and the FY2025 full-year result was $6.7 million, up 699.64% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$1.5 million, down from $5.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $5.4 million in Q4 2025 and bottomed at -$4.9 million in Q1 2023.
- The 5-year median for Change in Accured Expenses is -$856000.0 (2024), against an average of -$507294.1.
- The widest annual swing landed in 2023, when Change in Accured Expenses tumbled 726.21%; it then surged 435.54% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at -$488000.0 in 2022, then plunged by 96.72% to -$960000.0 in 2023, then jumped by 204.06% to $999000.0 in 2024, then soared by 435.54% to $5.4 million in 2025, then tumbled by 127.94% to -$1.5 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), $5.4 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | -1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.50 Mn |
| Mar 31, 2026 | -1.50 Mn |
| Dec 31, 2025 | 5.35 Mn |
| Dec 31, 2025 | 5.35 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | -1.70 Mn |
| Mar 31, 2025 | -1.70 Mn |
| Dec 31, 2024 | 999,000.00 |
| Dec 31, 2024 | 999,000.00 |
| Sep 30, 2024 | -856,000.00 |
| Sep 30, 2024 | -856,000.00 |
| Jun 30, 2024 | 398,000.00 |
| Jun 30, 2024 | 398,000.00 |
| Mar 31, 2024 | -1.65 Mn |
| Mar 31, 2024 | -1.65 Mn |
| Dec 31, 2023 | -960,000.00 |
| Dec 31, 2023 | -960,000.00 |
| Sep 30, 2023 | -2.46 Mn |
| Sep 30, 2023 | -2.46 Mn |
| Jun 30, 2023 | -686,000.00 |
| Jun 30, 2023 | -686,000.00 |
| Mar 31, 2023 | -4.94 Mn |
| Mar 31, 2023 | -4.94 Mn |
| Dec 31, 2022 | -488,000.00 |
| Dec 31, 2022 | -488,000.00 |
| Sep 30, 2022 | 393,000.00 |
| Sep 30, 2022 | 393,000.00 |
| Jun 30, 2022 | -1.25 Mn |
| Jun 30, 2022 | -1.25 Mn |
| Mar 31, 2022 | -2.29 Mn |
| Mar 31, 2022 | -2.29 Mn |
| Dec 31, 2021 | 646,000.00 |
| Dec 31, 2021 | 646,000.00 |
| Sep 30, 2021 | -2.31 Mn |
| Sep 30, 2021 | -2.31 Mn |
| Jun 30, 2021 | 3.19 Mn |
| Jun 30, 2021 | 3.19 Mn |
| Mar 31, 2021 | 1.72 Mn |
| Mar 31, 2021 | 1.72 Mn |
| Dec 31, 2020 | -1.97 Mn |
| Dec 31, 2020 | -1.97 Mn |
| Sep 30, 2020 | 2.59 Mn |
| Sep 30, 2020 | 2.59 Mn |
| Jun 30, 2020 | -673,000.00 |
| Jun 30, 2020 | -673,000.00 |
| Mar 31, 2020 | -142,000.00 |
| Mar 31, 2020 | -142,000.00 |
| Dec 31, 2019 | -261,477.00 |
| Dec 31, 2019 | -261,477.00 |
| Sep 30, 2019 | -260,232.00 |
| Sep 30, 2019 | -260,232.00 |
| Jun 30, 2019 | -8.39 Mn |
| Jun 30, 2019 | -8.39 Mn |
| Mar 31, 2019 | 2.07 Mn |
| Mar 31, 2019 | 2.07 Mn |
| Dec 31, 2018 | 1.61 Mn |
| Dec 31, 2018 | 1.61 Mn |
| Sep 30, 2018 | 3.79 Mn |
| Sep 30, 2018 | 3.79 Mn |
| Jun 30, 2018 | 2.24 Mn |
| Jun 30, 2018 | 2.24 Mn |
| Mar 31, 2018 | 160,627.00 |
| Mar 31, 2018 | 160,627.00 |
| Dec 31, 2017 | 1.70 Mn |
| Dec 31, 2017 | 1.70 Mn |
| Sep 30, 2017 | 563,412.00 |
| Sep 30, 2017 | 563,412.00 |
| Jun 30, 2017 | 81,149.00 |
| Jun 30, 2017 | 81,149.00 |
| Mar 31, 2017 | -303,452.00 |
| Mar 31, 2017 | -303,452.00 |
| Dec 31, 2016 | -2.60 Mn |
| Dec 31, 2016 | -2.60 Mn |
| Sep 30, 2016 | 1.96 Mn |
| Sep 30, 2016 | 1.96 Mn |
| Jun 30, 2016 | 226,616.00 |
| Jun 30, 2016 | 226,616.00 |
| Mar 31, 2016 | 291,522.00 |
| Mar 31, 2016 | 291,522.00 |
| Dec 31, 2015 | 942,072.00 |
| Dec 31, 2015 | 942,072.00 |
| Sep 30, 2015 | -185,976.00 |
| Sep 30, 2015 | -185,976.00 |
| Jun 30, 2015 | 720,283.00 |
| Jun 30, 2015 | 720,283.00 |
| Mar 31, 2015 | -355,325.00 |
| Mar 31, 2015 | -355,325.00 |
| Dec 31, 2014 | -1.12 Mn |
| Dec 31, 2014 | -1.12 Mn |